Closing Thoughts on TYK2 Inhibition in Psoriasis

In the final episode, ‘Closing Thoughts on TYK2 Inhibition in Psoriasis,’ the panelists explore the culmination of their discussion on modern psoriasis care and offer closing pearls for clinical practice. Dr. Mark Lebwohl emphasizes that while every patient presents a unique constellation of desires, symptoms, and comorbidities, dermatologists are currently in a better position than ever to achieve high levels of clearance. He advises clinicians to run through a quick mental algorithm for every patient that accounts for factors such as smoking status, high blood pressure, and preferences regarding oral versus injectable administration. Dr. Lebwohl stresses that clinicians should never settle for just okay results, as tighter disease control directly reduces the risk of long-term complications like psoriatic arthritis and cardiovascular events.

Dr. Tina Bhutani-Jacques reinforces this message by encouraging providers to shed any lingering hesitation regarding the use of systemic therapies. She points out that the current and emerging classes of medications, particularly selective TYK2 inhibitors, are remarkably safe when paired with appropriate patient monitoring. The experts conclude by reminding clinicians that they are in a unique position to improve not just the skin, but the overall life expectancy and health of their patients. By focusing on shared decision making and the prevention of systemic inflammation, providers can ensure that even patients who are initially hesitant or satisfied with partial clearance understand the vital health benefits of more effective, modern interventions.

Thank you for watching this Peers & Perspectives series on TYK2 inhibition in psoriasis. Please subscribe to our newsletter for information on upcoming video series.